1. Introduction {#s0005}
===============

Chronic neuropathic pain is a complex disease resulting from actual or presumed damage to the somatosensory nervous system. The constant perception of pain that characterizes neuropathic pain is associated with increased thalamic bursting activity ([@bb0070]; [@bb0105]; [@bb0140]), reduced thalamic blood flow ([@bb0095]; [@bb0100]; [@bb0160]; [@bb0300]) and increased cortical power, often termed thalamocortical dysrhythmia ([@bb0190]; [@bb0200]; [@bb0285]). The increase in cortical power is associated with an altered relationship with thalamic GABAergic content ([@bb0190]) and we have proposed that the thalamocortical dysrhythmia that occurs in chronic neuropathic pain results from altered interactions between the ventrocaudal thalamus, thalamic reticular nucleus and the cerebral cortex ([@bb0090]).

In addition to cortical resting activity changes, as read with electroencephalography (\>2 Hz) we have previously shown that chronic neuropathic pain is associated with increased infra-slow frequency (\<0.1 Hz) oscillatory activity throughout the ascending pain pathway, including the region of the primary afferent synapse, ventrocaudal thalamus, thalamic reticular nucleus and primary somatosensory cortex ([@bb0005]). Interestingly, these infra-slow oscillation increases occurred at approximately the same frequency range as reported calcium waves in astrocytes, i.e. 0.03--0.06 Hz ([@bb0045]). Astrocytes are known to modulate synaptic activity by the release of gliotransmitters and it is well-documented in preclinical animal models that neuropathic pain is associated with prolonged astrocyte activation in the dorsal horn/spinal trigeminal nucleus ([@bb0065]; [@bb0180]). Given these data, we have speculated that following nerve injury, prolonged astrocyte activation results in increased infra-slow oscillations in the ascending pain pathway which in turn is associated with thalamocortical dysrhythmia and the constant perception of pain ([@bb0090]).

Whilst it is clear from preclinical animal models that neuropathic pain is associated with astrocyte activation in the dorsal horn and brainstem ([@bb0095]; [@bb0180]), robust evidence is lacking in humans. There is, however, evidence from a post-mortem study which revealed prolonged astrocyte activation, but no microglial activation, in the dorsal horn of individuals with neuropathic pain associated with HIV ([@bb0220]). Indirect measurements of glial activation using Positron Emission Tomography (PET) have also revealed chronic glial activation in humans with neuropathic pain. Banati and colleagues ([@bb0020]) reported increases in binding of \[^11^C\](R)-PK11195 (a sensitive in vivo marker of glial cell activation) in the contralateral (to injury) thalamus of patients with phantom limb pain. Similarly, Loggia and colleagues recently used the same technique to show increased glial activation in the thalamus and primary somatosensory cortex, contralateral to pain, of individuals with chronic low back pain ([@bb0145]). Whilst these brain imaging studies are important and suggest chronic glial activation in the thalamus and above, technical limitations mean that they cannot explore changes at the level of the brainstem or, more importantly, the primary afferent synapse.

One non-invasive technique that has been used to measure glial activation is T2 relaxometry ([@bb0110]; [@bb0275]), a magnetic resonance imaging technique that can characterise changes in the brainstem and above. There is immunohistochemical evidence that decreased T2 relaxation times are associated with increased glial activation ([@bb0205]) and in this investigation we hypothesize that chronic orofacial neuropathic pain is associated with significantly reduced T2 relaxation time in the ascending pain pathway, including the region of the spinal trigeminal nucleus, ventrocaudal (Vc) thalamus, thalamic reticular nucleus and the orofacial region of the primary somatosensory cortex.

2. Methods {#s0010}
==========

2.1. Subjects {#s0015}
-------------

Thirty-seven subjects with chronic orofacial neuropathic pain (NP; 28 females, mean age 46.1 ± 2.5 years \[±SEM\]) and 40 healthy controls without ongoing pain (24 females, mean age 40.6 ± 2.7 \[±SEM\]) were recruited for this study. All NP subjects were diagnosed using the Liverpool criteria as having post-traumatic painful trigeminal neuropathy ([@bb0175]). Written informed consent was obtained for all procedures and the study was approved by Institutional Human Research Ethics Committees, University of Sydney.

For each NP subject, the intensity of their on-going pain was recorded on a 10 cm horizontal visual analogue scale (VAS) with 0 indicating "*no pain*" and 10 indicating "*worst imaginable pain*", three times a day for the seven days prior to a magnetic resonance imaging (MRI) session ([@bb0035]). These pain intensity scores were averaged over the 7-day period to create a mean pain intensity score. On the day of the MRI, all subjects were experiencing pain and were asked to draw the distribution of their ongoing pain. Subjects were also asked to complete a McGill Pain Questionnaire ([@bb0165]), the Beck Depression Inventory (BDI) ([@bb0025]) and the Pain Catastrophizing Questionnaire (PCS) ([@bb0250]). A subset of the control and NP subjects was used in a previous investigation ([@bb0005]).

2.2. MRI acquisition {#s0020}
--------------------

All subjects lay supine on the bed of a 3 Tesla MRI scanner (Philips Achieva) with their head immobilized in a tight-fitting 32-channel SENSE head coil. With each subject relaxed and at rest, a high resolution T1-weighted anatomical image set covering the entire brain was collected (turbo field echo; field of view 250 × 250 mm; matrix size 288 × 288; slice thickness 0.87 mm; repetition time 5600 ms; echo time 2.5 ms; flip angle 8°; raw voxel size 0.87 × 0.87 × 0.87 mm). Following this, T2-weighted image sets covering the entire brain were collected (field of view 250 × 250 mm; matrix size 556 × 556; slice thickness 5 mm; repetition time 3000 ms; echo times 20, 40, 60, 80, 100 ms; raw voxel size 0.4 × 0.4 × 5 mm thick). Multiple echo times were used to create multiple image sets for subsequent calculation of T2-relaxation time maps.

2.3. MRI analysis {#s0025}
-----------------

Using SPM12 ([@bb0060]) and custom software, the following equation was used to calculate T2 relaxation time brain maps: T~2~ = (TE~2~ − TE~1~)/ln(SI~1~/SI~2~) where TE~1~ and TE~2~ are the echo times for proton density and T2-weighted images, and SI~1~ and SI~2~ represent proton density and T2-weighted image signal intensities, respectively. A ceiling threshold of 500 ms was applied to eliminate cerebrospinal fluid. In each subject, T2 relaxation maps were co-registered to each individual\'s T1-weighted anatomical image set. The T1-weighted anatomical image was then spatially normalized to a template in Montreal Neurological Institute (MNI) space and the parameters applied to the T2 relaxation time maps. Finally, the T2 brain maps were spatially smoothed using an 8 mm full-width-at-half-maximum Gaussian filter. In those NP subjects with pain restricted to the left side of the face (n = 17), T2-weighted images were reflected across the midline so that T2 differences could be assessed ipsilateral and contralateral to the side of highest ongoing pain.

In addition to a wholebrain T2 relaxation analysis, we performed a brainstem-specific analysis. The T2 relaxation maps were cropped to include only the brainstem and cerebellum, and a mask of these regions was created using the Spatial Unbiased Infratentorial Template (SUIT) toolbox ([@bb0050]). These brainstem/cerebellum masks were then manually adjusted to accurately encompass the brainstem and cerebellum only. Using this mask, T2 relaxation brainstem images were spatially normalized to the SUIT template in MNI space and spatially smoothed using a 3 mm full-width-at-half-maximum Gaussian filter.

Significant differences in T2 relaxation time between controls and NP subjects were determined using a voxel-by-voxel analysis of the wholebrain and the brainstem only (p \< 0.05, random effects, false discovery rate corrected for multiple comparisons, minimum cluster 10 voxels, age and gender as nuisance variables). A brain mask that excluded CSF as well as the brainstem was applied to the wholebrain analysis. For both the wholebrain and brainstem only analyses, mean (± SEM) T2 relaxation times of significantly different clusters were extracted and plotted. Significant correlations between T2 relaxation times and pain intensity, BDI and PCS scores were also determined (p \< 0.05). In addition, to determine if medication use had a significant effect on T2 relaxation times, for each cluster, T2 relaxation times were compared between those NP subjects taking acute analgesic medication alone (n = 5) or those taking prophylactic analgesic medication (n = 11) with those not taking medication (n = 21) (p \< 0.05, two-tailed, two-sample *t*-tests).

3. Results {#s0030}
==========

3.1. Psychophysics {#s0035}
------------------

Individual NP subject characteristics are shown in [Table 1](#t0005){ref-type="table"}, and overall pain distributions and pain descriptors in [Fig. 1](#f0005){ref-type="fig"}. In 34 of the NP patients, their on-going pain was unilateral (17 right, 17 left), and the remaining 3 NP subjects reported bilateral pain. In all NP subjects, pain was located in the 2nd and 3rd trigeminal nerve divisions, with 7 subjects also reporting pain in the 1st division. The mean (± SEM) pain intensity over the 7 days prior to the MRI scanning session was 3.8 ± 0.4 out of 10 and the mean duration of pain was 4.1 ± 0.9 years. Using the McGill Pain Questionnaire, NP subjects most frequently described their pain as "throbbing", "tender" and "radiating". There was no significant difference in age (*t*-test; p \> 0.05) or gender composition (chi-squared test, p \> 0.05) between the two subject groups. Compared with controls, NP subjects had higher BDI scores (mean ± SEM: controls: 5.0 ± 1.0, NP: 26.6 ± 2.0, p \< 0.001) and PCS scores (controls: 12.2 ± 1.7, NP: 15.8 ± 1.5, p \< 0.001).Table 1NP subject characteristics.Table 1SubjectAge (years)GenderPain duration (years)SitePain Intensity (VAS)Acute analgesic medicationProphylactic medication127M3.4Right0.5--Palmitoylethanolamide221F12Right1.3--Palmitoylethanolamide335M8Right1.4--Palmitoylethanolamide445M14Left1.4--Palmitoylethanolamide533F7Left2.4----653F2Left2.3----721M0.3Left1.9--Palmitoylethanolamide864F17Right4.1----976F25Left5.7----1067F2Left6.3Diazepam--1147F2.8Left4.1----1240F1.5Right7.8IbuprofenPregabalin, carbamazepine1335F2Left4.9----1446F0.6Left3.6----1552F0.8Right2.7----1658M1.8Left9.6Ibuprofen--1758F10Right5.1----1842F2.8Right4.5----1944M3.3Bilateral7.5Acetylsalicylic acid, ibuprofenDextroamphetamine, metaprolol tartrate2047F0.4Right2----2165F10Left6.1Paracetamol--2264F0.2Right1.5----2324F2.6Left0----2428F0.2Bilateral7.2Ibuprofen, paracetamol, oxycodone hydrochloridePregabalin2558F0.5Right2.3Ibuprofen, paracetamolPregabalin2644F2.3Right4--Desvenlafaxine2739F0.6Left3.1Ibuprofen, paracetamol, codeine2855F1Right0.8----2941M0.5Right5.1----3036F0.3Left0----3120F0.5Left1.7----3239F2.6Left5.6----3374F0.4Bilateral4.2----3453M0.6Right2.1----3529M5.8Left4.8Tramadol--3673F3Right7.5--Efexor3753F2.3Right------Mean ± SEM46.1 ± 2.54.1 ± 0.93.8 ± 0.4Fig. 1Pain distribution and quality of pain in 37 subjects with chronic orofacial neuropathic pain.A) Individual pain distribution patterns in all 37 chronic pain (NP) subjects. B) Frequency (percentage of subjects) of descriptors chosen from the McGill Pain Questionnaire to describe the quality of on-going pain, in NP subjects.Fig. 1

3.2. T2 relaxation times {#s0040}
------------------------

Wholebrain analysis revealed that NP subjects displayed significantly decreased T2 relaxation times relative to controls in a number of brain regions ([Fig. 2](#f0010){ref-type="fig"}, [Table 2](#t0010){ref-type="table"}). These included the left (contralateral to highest pain) mid-cingulate cortex (mean ± SEM ms: controls: 101.2 ± 1.4, NP: 95.4 ± 1.1), left anterior cingulate cortex (controls: 96.8 ± 1.1, NP: 92.7 ± 1.0), left primary somatosensory cortex (controls: 107.5 ± 1.1, NP: 100.1 ± 1.3), left dorsolateral prefrontal cortex (controls: 122.4 ± 4.6, NP: 105.5 ± 3.2) and the left hippocampus/parahippocampus (controls: 145.2 ± 2.2, NP: 131.3 ± 1.9).Fig. 2Significant differences in T2 relaxation times in individuals with chronic neuropathic pain compared with controls.A) Regions where chronic neuropathic pain (NP) subjects had significantly reduced T2 relaxation times compared with controls. Reductions are indicated by the cool colour scale and overlaid onto a mean T1-weighted anatomical image set derived from all 77 subjects. Note the decreases within the orofacial region of the primary somatosensory cortex (S1), mid-cingulate cortex (MCC), anterior cingulate cortex (ACC), dorsolateral prefrontal cortex (dlPFC) and hippocampus. Slice locations in Montreal Neurological Institute space are indicated at the top right of each slice. B) Plots of mean ± SEM T2 relaxation times (ms) in control (black bars) and NP (blue bars) groups for significant clusters. ^⁎^denotes significant differences derived from the voxel-by-voxel random-effects analysis (p \< 0.05, false discovery rate corrected). ipsi: ipsilateral to side of highest on-going pain. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 2Table 2Location, cluster size and significance level of T2 relaxation time decreases in individuals with chronic neuropathic pain compared with controls. Cluster peak locations are indicated in Montreal Neurological Institute (MNI) space.Table 2Brain regionMNI co-ordinateCluster size*t*-scoreWhole brain T2 relaxation timeLeft mid cingulate cortex6−1139754.18−3−2438554.31Left medial prefrontal cortex−62424103.88Left primary somatosensory cortex−61021404.40Left dorsolateral prefrontal cortex−56249184.11Left hippocampus/parahippocampus20−32−173134.42  Brainstem T2 relaxation timeRight spinal trigeminal tract930−11174.67Right trigeminal nerve entry11−26−37545.03Right spinal trigeminal nucleus10−42−46304.62

Brainstem-specific analysis also revealed regions in which T2 relaxation times were significantly lower in NP subjects than in controls in three discrete brainstem regions ([Fig. 3](#f0015){ref-type="fig"}, [Table 2](#t0010){ref-type="table"}). Decreased T2 relaxation times in NP subjects occurred in the region encompassing the right spinal trigeminal nucleus (controls: 106.8 ± 1.1, NP: 101.2 ± 1.3), the right spinal trigeminal tract (controls: 118.2 ± 1.7, NP: 108.9 ± 2.1) and in the region of the right trigeminal nerve entry (controls: 107.3 ± 2.0, NP: 98.1 ± 1.8). In no brainstem region was there a significant increase in T2 relaxation time in NP subjects compared with controls.Fig. 3Significant differences in T2 relaxation times in individuals with chronic neuropathic pain compared with controls, within the brainstem only.A) Regions in which chronic neuropathic pain (NP) subjects had significantly reduced T2 relaxation times compared with controls. Reductions are indicated by the cool colour scale and overlaid onto a brainstem template image set. Note the decreases within the region where orofacial nociceptor afferents terminate -- the spinal trigeminal nucleus (SpV), as well as the area where the trigeminal nerve (V) enters the pons. Slice locations in Montreal Neurological Institute space are indicated at the top right of each slice. B) Plots of mean ± SEM T2 relaxation times (ms) in control (black bars) and NP (blue bars) groups for significant clusters. ^⁎^denotes significant differences derived from the voxel-by-voxel random-effects analysis (p \< 0.05, false discovery rate corrected). ipsi: ipsilateral to side of highest on-going pain. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 3

In NP patients, there were no significant relationships between pain intensity or duration and T2 relaxation times in the left mid-cingulate cortex (intensity: r = 0.08, duration: r = 0.08), left anterior cingulate cortex (intensity: r = 0.11, duration: r = 0.36), left primary somatosensory cortex (intensity: r = 0.05, duration: r = 0.22), left dorsolateral prefrontal cortex (intensity: r = 0.25, duration: r = 0.26), left hippocampus/parahippocampus (intensity: r = 0.23, duration: r = 0.26), right trigeminal nerve entry (intensity: r = 0.22, duration: r = 0.13), right spinal trigeminal tract (intensity: r = 0.11, duration: r = 0.20), and right spinal trigeminal nucleus (intensity: r = 0.09, duration: r = 0.14, all p \> 0.05). Furthermore, in NP subjects there were no significant linear relationships between PCS or BDI values and T2 relaxation times in the left mid-cingulate cortex (PCS: r = 0.26, BDI: r = 0.31), left anterior cingulate cortex (PCS: r = 0.16, BDI: r = 0.06), left primary somatosensory cortex (PCS: r = 0.38; BDI: r = 0.22), left dorsolateral prefrontal cortex (PCS: r = 0.19, BDI: r = 0.28), left hippocampus/parahippocampus (PCS: r = 0.08, BDI: r = 0.01), right trigeminal nerve entry (PCS: r = 0.03, BDI: r = 0.26), right spinal trigeminal tract (PCS: r = 0.04, BDI: r = 0.24), and right spinal trigeminal nucleus (PCS: r = 0.07, BDI: r = 0.11; all p \> 0.05).

Finally, exploring the effects of medication use on T2 relaxation times in NP subjects revealed that in no cluster was T2 relaxation time significantly different in those taking either acute analgesic or prophylactic medications compared with those not taking medication: left mid-cingulate cortex (mean ± SEM ms: acute meds: 96.5 ± 3.4, prophylactic meds: 89.9 ± 1.4, no meds: 91.6 ± 1.1, acute v control p = 0.08; prophylactic vs controls p = 0.36), left anterior cingulate cortex (acute meds: 94.2 ± 0.6, prophylactic meds: 91.0 ± 1.3, no meds: 93.3 ± 1.6, p = 0.78, p = 0.36), left primary somatosensory cortex (acute meds: 99.8 ± 3.6, prophylactic meds: 103.0 ± 0.2.4, no meds: 98.5 ± 1.7, p = 0.73, p = 0.12), left dorsolateral prefrontal cortex (acute meds: 101.4 ± 8.5, prophylactic meds: 101.9 ± 5.4, no meds: 108.8 ± 4.4, p = 0.46, p = 0.34), left hippocampus/parahippocampus (acute meds: 134.6 ± 6.5, prophylactic meds: 130.9 ± 2.8, no meds: 130.6 ± 2.8, p = 0.54, p = 0.95) and right spinal trigeminal nucleus (acute meds: 79.8 ± 5.8, prophylactic meds: 87.7 ± 5.4, no meds: 91.4 ± 3.4, p = 0.12, p = 0.53).

4. Discussion {#s0045}
=============

The results of this investigation reveal significant decreases in T2 relaxation times in patients with chronic orofacial neuropathic pain at multiple points along the ascending pain pathway. Changes occurred in NP subjects in the region of the trigeminal nerve entry, the region of the ipsilateral (to pain) spinal trigeminal nucleus and in the contralateral orofacial representation of the primary somatosensory cortex. In addition, changes occurred in higher processing regions such as the cingulate and prefrontal cortices. These anatomical changes are consistent with pathological processes associated with astrocyte activation.

T2 relaxation times are influenced by the chemical characteristics of tissue. One factor that will significantly affect T2 relaxation time is the static dipolar fields created by neighbouring dipoles; in solids and polymers the static dipolar field is large. Thus, an increase in the proportion of solids and polymers within a region of the brain for example, would result in an increase in T2 relaxation rate, i.e. decrease in T2 relaxation time, in that region ([@bb0075]; [@bb0240]). Such an increase in solids/polymers within a specific brain region could result from numerous factors, including astrogliosis. In mild to moderate astrogliosis, there is an increase in glial fibrillary acidic protein, an intermediate filament composed of a variety of proteins, which would contribute to an increase in static dipolar field and a decrease in T2 relaxation time ([@bb0230]; [@bb0235]; [@bb0255]). Consistent with this, an experimental animal study that investigated changes following stroke reported decreased T2 relaxation times in areas of increased astrocyte and microglial activation and iron deposition ([@bb0115]). Furthermore, a human post mortem study of two individuals with multiple system atrophy reported reduced T2 relaxation times in the putamen, an area that also displayed pronounced reactive astrogliosis and microgliosis ([@bb0205]). Whilst there are other anatomical changes besides astrogliosis that could have contributed to the change in T2 relaxation times shown in this investigation, several lines of evidence suggest that astrogliosis is a likely contributing factor.

We found decreased T2 relaxation time in the region encompassing the ipsilateral (to pain) spinal trigeminal nucleus, the area in which orofacial nociceptor afferents terminate. It is known from both human post-mortem and experimental animal investigations that the presence of chronic pain following nerve injury is associated with prolonged astrocyte (and not microglial) activation at the level of the primary afferent synapse ([@bb0065]; [@bb0180]; [@bb0220]). In a previous investigation, we found an increase in on-going infra-slow oscillatory activity in the region encompassing the spinal trigeminal nucleus in individuals with chronic orofacial neuropathic pain ([@bb0005]). Importantly, these increased infra-slow oscillations were at similar frequencies as calcium waves in activated astrocytes, which are associated with the release of gliotransmitters and the subsequent modulation of neural activity ([@bb0185]). We speculated that although chronic neuropathic pain is *not* associated with increased on-going activity in the ascending pain pathways, the modulation of this pathway by gliotransmitters results in altered activity patterns, thalamocortical dysrhythmia and the constant perception of pain ([@bb0005]; [@bb0090]). A decrease in spinal trigeminal nucleus T2 relaxation time is consistent with this hypothesis, although whether this change in relaxation time represents astrocyte activation remains debatable.

In our previous investigation, we also found altered infra-slow oscillation increases associated with chronic neuropathic pain in the region of the ventrocaudal thalamus, thalamic reticular nucleus and in the primary somatosensory cortex ([@bb0005]). In addition, others have reported increased \[^11^C\](R)-PK11195 binding, a marker of glial activation, in the thalamus and primary somatosensory cortex in individuals with NP ([@bb0020]; [@bb0145]). Whilst altered \[^11^C\](R)-PK11195 binding may reflect changes in microglial or astrocyte activation, surprisingly we found no change in T2 relaxation time in the thalamus in this investigation, despite showing changes in the spinal trigeminal nucleus and primary somatosensory cortex. Why no change in T2 relaxation rate occurred in the thalamus is unknown, but it might be the case that the thalamus is somehow more resistant to the development of astrogliosis than the primary afferent synapse or somatosensory cortex, or that recurrent circuits between the thalamus and cortex somehow reduces the potential for thalamic astrocyte activation following nerve injury. Indeed, in contrast to reports of prolonged astrocyte activation at the primary afferent synapse, it has been reported in the chronic constriction model of neuropathic pain that the ventroposterior thalamus displays microglial and not astrocyte activation at 7 and 14 days post injury, and that inhibiting microglial activation reduces thermal hyperalgesia ([@bb0135]). This raises the possibility that increased infra-slow oscillations in the ventrocaudal thalamus in individuals with NP are driven by such changes at the primary afferent synapse. This is consistent with the finding of a preclinical study that shows infra-slow oscillatory activity in the ventroposterior thalamus was eliminated by severing the connection between the primary afferent synapse and the thalamus ([@bb0105]).

Whilst the focus of this investigation was on changes in the ascending pain pathway, it is likely that other brain regions are also involved in the maintenance of neuropathic pain. We also found decreases in T2 relaxation time in the cingulate, dorsolateral prefrontal and hippocampal cortices in individuals with neuropathic pain. There is evidence from preclinical models of chronic pain of astrocyte activation in the anterior cingulate cortex and suggestions that these changes are associated with sleep disturbances ([@bb0130]; [@bb0290]). Whilst we did not measure sleep patterns in our chronic pain subjects it is possible that the altered T2 relaxation in the cingulate cortex may reflect changes in sleep patterns that occur in individuals with various forms of chronic pain ([@bb0195]). Alternatively, there is growing evidence that the cingulate cortex codes the affective dimension of pain and thus cingulate astrocyte activation may reflect this aspect of the chronic pain condition, an idea that has support from preclinical investigations ([@bb0040]; [@bb0170]).

Indeed it is well established that neuropathic pain is often associated with psychological changes such as depression and pain catastrophizing ([@bb0015]; [@bb0120]) and we found significant differences in pain catastrophizing scores and depression scores between the healthy controls and NP subjects. We did find significant changes in T2 relaxation times in the cingulate cortex, whose function is associated with depression ([@bb0055]; [@bb0085]). Although we found no correlation between T2 relaxation in any brain region and depressive scores, there is evidence of increased infra-slow oscillation power in the anterior cingulate cortex of individuals with treatment-resistant depression ([@bb0085]). Furthermore, these regions were also not correlated to pain intensity or duration of neuropathic pain. Whilst the lack of linear correlations does not exclude the possibility that the changes in these areas are related to pain and psychological measures, it may be that the underlying mechanisms responsible for T2 relaxation time alterations reflect anatomical changes that are simply not linearly coupled to changes in neural activity.

In contrast to the cingulate cortex, we know of no investigation exploring astrocyte changes in the dorsolateral prefrontal cortex or hippocampus in individuals with neuropathic pain or in preclinical models. Whilst the role of the dorsolateral prefrontal cortex in neuropathic pain remains unclear, there is evidence that its anatomy and function is altered in various pain conditions ([@bb0010]; [@bb0150]; [@bb0215]). Furthermore, there is evidence for a role for the dorsolateral prefrontal cortex in descending pain modulation, which is altered in individuals with chronic pain ([@bb0030]; [@bb0305]). We also found T2 relaxation time differences in the ventral aspect of the hippocampus, a region thought to control hypothalamopituitary adrenal (HPA) axis function ([@bb0245]). Consistent with the idea that these T2 relaxation time changes represent astrogliosis, there are multiple investigations that report hippocampal volume increases in individuals with chronic pain, although there are some inconsistencies ([@bb0210]; [@bb0225]; [@bb0270]; [@bb0295]). Since chronic pain is also associated with the presence of stress-related disorders and HPA axis dysfunction ([@bb0080]; [@bb0125]; [@bb0260]), it is possible that the changes in ventral hippocampal T2 relaxation times are related to changes in HPA axis function in our chronic pain subjects.

We found that neither acute analgesic nor prophylactic medication use had significant effect on T2 relaxation times in NP subjects, making it unlikely that medication itself has a significant effect on T2 relaxation times and the relationship between T2 relaxation times and pain and psychological measures. Whilst the effects of medication use on regional astrocyte activation and T2 relaxation rate needs to be explored in a longitudinal manner, our hypothesis that neuropathic pain results from chronic astrocyte activation is consistent with finding that neuropathic pain medications such as valproate, phenytoin and gabapentin, reduce astrocyte calcium signalling ([@bb0265]). This raises the propect that other medications with potential astrocytic modulatory functions, such as Clozapine, Riluzole, Chromipramine and Palmitoylethanolamide, may also be effective at treating neuropathic pain.

In addition to reduced T2 relaxation rates, we have previously shown in individuals with chronic orofacial pain, the SpV displays reduced gray matter density, reduced mean diffusivity, increased infra-slow oscillations and increased functional connectivity strengths with brainstem endogenous pain modulation circuitry ([@bb0005]; [@bb0155]; [@bb0280]). Despite altered functional connectivity, we did not observe anatomical or infra-slow oscillatory changes in brainstem pain modulating regions such as the periaqueductal gray, dorsolateral pons, subnucleus reticularis dorsalis or rostroventromedial medulla. Given this, we speculate that the anatomical changes and resting oscillation changes that occur in SpV reflect astrocyte activation that results from excitotoxic damage and is exacerbated by reduced endogenous analgesic circuitry action at the level of SpV. Future studies are needed to provide solid evidence that such a chain of events occurs.

Finally, there are several limitations that need to be noted. Firstly, as mentioned above, altered T2 relaxation times are not a direct index of astrocyte activation and further combined MRI and histochemical investigations are needed to determine precisely how astrocyte activation alters T2 relaxation times. Although PET studies may provide a more accurate measure of glial activation, at this stage they are not suited to measure changes at the primary afferent synapse in the brainstem or spinal cord. Secondly, it is difficult to accurately localize clusters to specific nuclei, particularly those in the brainstem, due to the relatively low spatial resolution and the fine compartmentalization of brainstem nuclei. Increasing MRI field strengths and greater accuracy of brainstem spatial normalization procedures will improve our confidence in brainstem-specific analysis in future investigations. Thirdly, whilst we found that medication use had no effect on T2 relaxation times, this finding should be interpreted with caution given the small number of subjects taking acute and preventive medications. Despite these limitations, the discrete localization of decreases in T2 relaxation times found in chronic orofacial neuropathic pain subjects in this investigation, together with existing human and pre-clinical evidence, makes us confident that astrocytes play a critical role in the development and the maintenance of neuropathic pain following nerve injury.
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